SlideShare uma empresa Scribd logo
1 de 69
Baixar para ler offline
LUNG TRANSPLANTATION
Dr. Pratik Kumar
1
Overview :
• Introduction
• Purpose of lung transplantation
• History
• Indications
• Disease specific selection criteria
• Contraindications
2
Overview :
• Description
• Laboratory studies
• Donor-related issues
• Preoperative care
• Post operative care
• Complications
• Normal results
3
Introduction :
• Lung transplantation involves removal of one
or both diseased lungs from a patient and the
replacement of the lungs with healthy organs
from a donor
• Lung transplantation may refer to single,
double, or even heart-lung transplantation .
• Lung transplantation is an accepted modality
of treatment for end stage lung disease that is
unresponsive to medical therapy
4
Purpose :
• To replace a lung that no longer functions with
a healthy lung.
• To perform a lung transplantation, there
should be potential for rehabilitated breathing
function.
• Other medical treatments should be
attempted before transplantation.
• Many candidates for this procedure are
dependent on oxygen therapy
5
History of procedure :
• Animal experimentation by various pioneers,
including Demikhov and Metras, in 1940s and
1950s demonstrated that the procedure is
feasible technically.
• First human lung transplantation was done in
1963. The donation was essentially after
cardiac death, and the recipient of the left lung
transplant survived only 18 days.
6
Cont……….d:
• From 1963-1978, multiple attempts at lung
transplantation failed because of rejection and
problems with anastomotic bronchial and
tracheal healing.
• The first successful single lung transplant was
reported by Dr. Joel Cooper at the University
of Toronto in 1986 .
7
Cont……….d:
• In 1988, Dr. Alexander Patterson described the
technique of double-lung transplantation.
• Dr. Denton Cooley and associates were the
first to attempt heart-lung transplantation in
1968.
• First heart-lung transplant in India- 3 May
1999 at Madras Medical Mission.
8
AGE DISTRIBUTION OF LUNG TRANSPLANT
RECIPIENTS
0
5
10
15
20
25
18-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-65 66+
Recipient Age
%oftransplants
J Heart Lung Transplant 2008;27: 937-983
9
Indication of lung transplantation :
• Obstructive lung disease:
A. Chronic obstructive pulmonary disease
• Restrictive lung diseases:
A. Idiopathic pulmonary fibrosis (IPF)
B. Interstitial lung disease
10
Indication of lung transplantation :
• Septic lung disease:
A. Cystic fibrosis (CF)
B. Bilateral bronchiectasis
• Pulmonary vascular disease:
A. Primary pulmonary hypertension (PPH)
B. Eisenmenger’s syndrome
11
Diagnosis of Lung Transplant Recipients in US
(1986-2007)
40%
13%13%
8%
14%
2%
4%
1% 4% 1% COPD
Alpha I Anti Def
IPF
Other
Cystic Fibrosis
IPAH
Talcosis
BO
Eisenmenger's
Bronchiectasis
J Heart Lung Transplant 2008;27: 937-983 12
Disease specific selection criteria
COPD-
Pt. with BODE index 7 to 10 of at least 1
of the following:
1. FEV1 < 25% predicted ( without
reversibility)
2. PaCO2 >55 mm of Hg
3. Elevated pulmonary artery pressure
(PAP)
4. Cor pulmonale
13
Cont……….d:
Other indices shown to correlate mortality-
1)subjective breathlessness
2)weight loss
3)exercise tolerance
4)hospitalization
5) lung morphology
all patients requiring hospitalization for
exacerberation should be considered for
surgery
1 year mortality after hospitalization -23%
14
The BODE Index For COPD
Can Fam Physician 2008;54:706-11
16
Cont……….d:
 IPF-
• Highest attrition rate with waiting list
mortality 30%
• Initially, owing to unpredictable nature of
course, view was to refer all patients for
transplantation at diagnosis
• Patients with exercise induced desaturation
are ideal candidates
17
Cont……….d:
 Current consensus-
1) Symptomatic progressive disease despite 3
months of medical therapy
2) Rest or exercise induced desaturation
3) Symptomatic with-
VC< 60-70%predicted
DLCO < 50-60% pred.
18
Cont……….d:
 Cystic fibrosis
 Prognostic criteria-
1)age per year
2)sex
3)FEV1
4)weight for age
5)Pancreatic insufficiency
6)D.M.
7)S.aureus
8)B.cepacia
9)No. of acute exacerberations
19
Cont……….d:
• Patients divided into 5 prognostic groups
• Only group 1&2 with 5 year survival rate <30%
benefited
• Resistant B. cepacia infection is absolute
contraindication
20
Cont……….d:
 PPH
• Advancement in medical management-
reduced need for transplantation
• 1990- 10.5% of all cases
• 2001- 3.6% of all cases
21
Cont……….d:
• Criterias for PPH
Symptomatic progressive disease
despite optimal medical treatment for
3 months
Cardiac index < 2 lit/min/m2
Right atrial pessure>15 mm Hg
PAP mean > 55 mm Hg
22
Cont……….d:
 Eisenmengers syndrome
• Better prognosis than patients with
PPH with similar PAP levels
• Epoprostenol therapy improved
survival & reduced need for
transplantation
• Heart -lung transplantation is preferred
23
Cont……….d:
 Sarcoidosis
• Most patients benign course 10-20%
permanent sequel
• 2.5% of all transplants
• Only stage 4 disease is considered
• FVC < 50% & FEV1 < 40%
24
Cont……….d:
 Lymphangioleiomyomatosis
• FEV1/FVC < 45%
• Average from diagnosis to transplant -
11yr
25
Contra-indication (Absolute ):
• Malignancy in the last 2 years
• Non-curable chronic extra pulmonary
infection including chronic active
hepatitis B , C , and HIV
• Untreatable advanced dysfunction of
another major organ system
• Current cigarette smoking
26
• Poor nutritional status
• Poor rehabilitation potential
• Significant psychosocial problems
• Substance abuse history of medical
noncompliance
27
Relative Contraindications :
• Age : advanced age is associated with
higher mortality rates .
• Most centers have an age cut-off
50 years for -Heart-lung transplantation,
60 years for- Bilateral lung transplantation,
65 years for -Single-lung transplantation.
28
• Ventilator dependence : patients who
are dependent on a ventilator prior to
the transplant have higher mortality
rates .
• A prolonged wait while the patient is on
a mechanical ventilator may lead to
various complications such as infections,
cardiovascular de-conditioning.
29
• Psychosocial issues : Individuals who
currently smoke, abuse drugs, or drink
alcohol heavily are not candidates for
transplantation.
• Patients with other psychosocial issues,
such as poor compliance and psychiatric
disorders that may complicate post
transplant therapy, are not considered
good candidates.
30
• Infection : patients who have active
tuberculosis infection are not candidates
for transplantation.
• Body weight : Patients who have poor
nutritional status and would have a poor
outcome following transplantation.
31
• Obesity (BMI >30) : also may be a
concern because of postoperative
atelectasis and pneumonia
• Extra pulmonary organ dysfunction :
Patients with a significant
heart, liver, or kidney disease are not
transplant candidates.
32
Description :
• Single lung transplantation is performed
via a standard thoracotomy (incision in
the chest wall) with the patient under
general anesthesia.
• Cardiopulmonary bypass (diversion of
blood flow from the heart) is not always
necessary for a single lung transplant.
33
Cont………..d:
• If bypass is necessary, it involves re-routing of
the blood through tubes to a heart-lung bypass
machine. Double lung transplantation involves
implanting the lungs as two separate lungs, and
cardiopulmonary bypass is usually required
• The patient's lung or lungs are removed and the
donor lungs are stitched into place. Drainage
tubes are inserted into the chest area to help
drain fluid, blood, and air out of the chest.
34
Figure
Patient positioned for bilateral lung transplant, through a clamshell incision
with the arms abducted. The skin incision is depicted in the mammary fold
heading laterally toward the mid-axillary line. The dotted line shows the
level of the 4th intercostal space. The position of the femoral artery, on both
sides, is also marked. The groin is prepped and draped, since during the
transplant procedure, an arterial femoral line may become necessary for
monitoring or even for cannulation for cardiopulmonary bypass.
35
ADULT LUNG TRANSPLANTATION: Indications for Single Lung Transplants (Transplants:
January 1995 - June 2007)
50%
28%
2%
1%
2%
7%
10%
Alpha-1 COPD CF IPF PPH Re-TX Other*
*Other includes:
Sarcoidosis: 2.1%
Bronchiectasis: 0.4%
Congenital Heart Disease: 0.2%
LAM: 0.7%
OB (non-ReTx): 0.5%
Miscellaneous: 5.8%
J Heart Lung Transplant 2008;27: 937-983
ADULT LUNG TRANSPLANTATION: Indications for Bilateral/Double Lung Transplants (Transplants:
January 1995 - June 2007)
24%
14%
18%
8%
28%
6% 2%
Alpha-1 COPD CF IPF PPH Re-Tx Other*
*Other includes:
Sarcoidosis: 3.0%
Bronchiectasis: 4.8%
Congenital Heart Disease: 1.3%
LAM: 1.2%
OB (non-ReTx): 1.1%
Miscellaneous: 6.6%
J Heart Lung Transplant 2008;27: 937-983
Laboratory studies :
• The following diagnostic tests are usually
performed to evaluate a patient for lung
transplantation:
• Arterial blood gases (ABG ) test: which
measures the amount of oxygen that the
blood is able to carry to body tissues.
38
• Pulmonary function tests (PFTs): which
measure lung volume and the rate of air flow
through the lungs; the results measure the
progress of the lung disease.
• Computerized tomography (CT) scan. A chest
CT scan is taken of horizontal slices of the
chest to provide detailed images of the
structure of the chest.
39
• Ventilation perfusion scan (lung scan, V/Q
scan) is a test that compares right and left
lung function
• Electrocardiogram (ECG): is performed by
placing electrodes on the chest. A recording of
the electrical activity of the heart is obtained
to provide information about the rate and
rhythm of the heartbeat
40
• Echocardiogram (ECHO) is performed to
evaluate the impact of lung disease on the
heart. It examines the
chambers, valves, aorta, and the wall motion of
the heart.
ECHO also provides information concerning the
blood pressure in the pulmonary arteries. This
information is required to plan the
transplantation surgery.
41
• Blood test : Complete blood count ,
Coagulation profile.
• HIV, hepatitis B, hepatitis C
42
Donor-related issues:
• Younger than 65 years for lung transplantation
and younger than 45 years for heart-lung
transplantation
• Absence of severe chest trauma or infection
• Absence of prolonged cardiac arrest (heart-
lung only)
• Minimal pulmonary secretions Negative
screens for HIV, hepatitis C, and hepatitis B
43
• Blood type (ABO) compatibility
• Close match of lung size between donor and
recipient
• PaO2 > 300 mm Hg on 100% fraction of
inspired oxygen
• Clear chest radiograph
• No history of malignant neoplasms
44
Preoperative care:
• Preoperative assessment consist of both medical
& psychosocial evaluation.
• Assessment of patient‘s physical health is
assessed to determine candidacy for
transplantation.
• In preoperative phase the patient is assessed for
cardiac output & renal functions .
• Psychosocial evaluation focuses on assessing the
patient‘s history of compliance with medical
therapy & ability to cope with stress.
45
Post operative care :
• The patient is observed for excessive bleeding.
• Monitor vital signs ,ECG ,ABG values ,urine
output, O2 level analysis & chest tube
drainage.
• The patient may be started on mechanical
ventilation for 24 to 48 hours.
46
• Serum electrolytes ,complete blood count,
chest radiographs are obtained daily.
• Fluids are restricted.
• Lung sounds are auscultated.
• Severity of peripheral edema is monitored.
• Pain control is important to allow deep
breathing & coughing with chest
physiotherapy.
47
• The patient with lung transplantation is at high
risk to develop infection.
• So isolation is used to decrease exposure to
pathogens.
• Monitor the patient for clinical manifestation of
infection such as:
Change in vital signs especially fever
Local infection at i/v site & incision line
Changes in respiratory status like
excessive secretions, tachypnea,dyspnea
48
Immunosuppression
• Induction phase-
A) ATG
B) Selective IL2 receptor antagonists
• Maintenance phase-
A) Steroid + calceneurin inhibitor
B) Steroids ( low dose ) life long
C) Tacrolimus for 1-5 years
49
Newer drugs
1) Sirolimus (Rapamycine)- An analog of
Tacrolimus
2) Everolimus- used in combination with
cyclosporin & prednisolone shown to have
freedom from biopsy proven acute rejection
in 88% cases
50
Complications
• Causes of respiratory failure after LTx
Early
• ischemia reperfusion
injury
• infection
• technical problems
• acute rejection
>3months
• Infections
• BOS
Curr.opin.Crit.care 2006 Feb;12, 19-24
51
Ischemia reperfusion injury
Most frequent cause of early mortality
presents as ALI / ARDS
Reduced incidence since 1990-
1) low K- dextran solution
2) nitric oxide added to flush solution
3) prevention of hyperinflation during harvesting
4)controlled reperfusion with leucocyte
depletion
52
Ischaemia reperfusion injury contd.
• Treatment-
A) diuretics
B) maximal ventilatory support
• Newer modalities
A) inhaled nitric oxide
B) inhaled prostacyclin
• Course-
resolves in 48-72 hrs
53
Infections
• Bacterial-
A) psuedomonas predominate in early post
op(75%)
B) nocardia-2.1%
C) legionella , mycobacteria rare
• routine antibiotic prophylaxis reduced the
incidence
• sputum cultures & antibiotic sensitivity done every
3 months
54
Viral infections
CMV predominates
• within 30-100 days after transplant
• occurs as reactivation or prim. infection
(donor)
• incidence varies between 13-75% in various
studies
• routine prophylaxis replaced by close
monitoring
• Treatment-gancyclovir 5mg/kg for 2-3 weeks55
• HSV&VZV can cause pnuemonia
• Acyclovir prophylaxis effective in patients not on
gancyclovir
• EBV related post-transplant lymphoproliferative
disease
• 4-10% cases
• usually fatal outcome
• recently Rituximab ( anti CD20 Ab) found effective
56
Fungal infections
• Aspergillus most common
1) ulcerative trachitis
2) bronchitis
3) pnuemonitis
4) disseminated diesase
5) ABPA- reported
• I.V. or aerolised ampho-B used for prophylaxis
57
Other rarer organisms
• Histoplasma
• Sedosporium
• Pnuemocystis jirovecii
58
Rejection
• Acute rejection-
• < 7 days onset
• low grade fever, dyspnoea
• CXR- 1) Clear
2) illdefined infiltrates
3) pleural effusion
• reduced FEV1
59
Acute rejection
• TBLB - gold standard in diagnosis
• Noninvasive means-area of active research
1) Cytokine milieu in BAL fluid
2) gene upregulation as a biomarker
• Treatment- bolus I.V. steroids + increase in
maintenance immunosuppression
• role of surveillance bronchoscopy to detect
rejection early is controversial
60
Chronic rejection
 Bronchiolitis Oblitrance Symdrome (BOA) :
• Predominantly a small airway disease
• occurs in 50% patients surviving for 5 years
• onset > 6months
• major cause of mortality
• CXR- can be normal late cases- bronchiectesis
• HRCT- mottled appearance with peripheral
lucency
61
TBLB- gold standard
• Role of induced sputum & BAL-
1) Induced sputum – RANTES levels and
eosinophils correlate with BOS
development
2) BAL- IL8 & neutrophil levels have
negative correlation
62
• Treatment- variable course even without
treatment
• various immunosuppressive regimens
tried
• macrolides under evaluation
63
• Factors associated-
1) CMV pnuemonitis -no. of episodes
2) HLA mismatch
3) GERD- laproscopic fundoplication reduces
incidence
64
Self care :
• Before discharge the patient should be teach
about the medication regimen.
• The patient should report for fever, dyspnea,
cough ,increased sputum production ,chest
pain, excessive weight gain, fatigue to
physician. During follow up the client is
monitored for manifestation of rejection &
progress in functional status.
65
• Exercise capacity has been the most
interesting functional outcome observes in
lung transplant recipient .
• Typically transplant recipient can walk 100
to 120m/min within 6 months of
transplantation.
66
Normal results:
• Demonstration of normal results for lung
transplantation patients include
a) adequate lung function,
b) improved quality of life,
c) lack of infection and rejection.
67
http://articles.timesofindia.indiatimes.com/2012-07-31/mumbai/32960286_1_lung-transplants-
transplant-team-surgery
Cost of Lung Transplantation in India
• Surgery alone cost Rs 10 lakh.
• The ICU and medications will work up to
an equal amount
68
THANK YOU
69

Mais conteúdo relacionado

Mais procurados (20)

Intercostal drainage
Intercostal drainageIntercostal drainage
Intercostal drainage
 
Pulmonary resection
Pulmonary resectionPulmonary resection
Pulmonary resection
 
Basic mechanical ventilation settings
Basic mechanical ventilation settingsBasic mechanical ventilation settings
Basic mechanical ventilation settings
 
ECMO - extracorporeal membrane oxygenation
ECMO - extracorporeal membrane oxygenationECMO - extracorporeal membrane oxygenation
ECMO - extracorporeal membrane oxygenation
 
CARDIOPULMONARY BYPASS
CARDIOPULMONARY BYPASSCARDIOPULMONARY BYPASS
CARDIOPULMONARY BYPASS
 
modes of ventilation
modes of ventilationmodes of ventilation
modes of ventilation
 
Cardiac surgeries
Cardiac surgeriesCardiac surgeries
Cardiac surgeries
 
Coronary Artery Bypass Graft
Coronary Artery Bypass GraftCoronary Artery Bypass Graft
Coronary Artery Bypass Graft
 
Extubation
Extubation Extubation
Extubation
 
Peep & cpap
Peep & cpapPeep & cpap
Peep & cpap
 
Interstitial lung diseases
Interstitial lung diseases Interstitial lung diseases
Interstitial lung diseases
 
Pneumonectomy
PneumonectomyPneumonectomy
Pneumonectomy
 
Respiratory failure
Respiratory failureRespiratory failure
Respiratory failure
 
Cardiopulmonary bypass
Cardiopulmonary bypassCardiopulmonary bypass
Cardiopulmonary bypass
 
Interstitial lung disease
Interstitial lung diseaseInterstitial lung disease
Interstitial lung disease
 
CABG
CABGCABG
CABG
 
Lung Carcinoma
Lung CarcinomaLung Carcinoma
Lung Carcinoma
 
Heart Transplant
Heart TransplantHeart Transplant
Heart Transplant
 
Extubation presentation
Extubation presentationExtubation presentation
Extubation presentation
 
Mechanical Ventilator by AJ
Mechanical Ventilator by AJMechanical Ventilator by AJ
Mechanical Ventilator by AJ
 

Semelhante a Lung transplantation.ppt

Lung transplantation
Lung transplantationLung transplantation
Lung transplantationRikin Hasnani
 
Lung-transplant-Part-1_Pawan_Jul-2017_Full.pdf
Lung-transplant-Part-1_Pawan_Jul-2017_Full.pdfLung-transplant-Part-1_Pawan_Jul-2017_Full.pdf
Lung-transplant-Part-1_Pawan_Jul-2017_Full.pdfAnjanaAnilkumar14
 
ICU Care of the Lung Transplant Recipient
ICU Care of the Lung Transplant RecipientICU Care of the Lung Transplant Recipient
ICU Care of the Lung Transplant RecipientSpectrum Health System
 
Coronary artery bypass grafting following COVID-19 infection
Coronary artery bypass grafting following COVID-19 infectionCoronary artery bypass grafting following COVID-19 infection
Coronary artery bypass grafting following COVID-19 infectionDharmendra Joshi
 
Preoperative assessment for cardio thoracic surgery
Preoperative assessment for cardio thoracic surgeryPreoperative assessment for cardio thoracic surgery
Preoperative assessment for cardio thoracic surgeryArsalan Khan
 
2021 ksctva september, underwent lung resected pt.
2021 ksctva  september, underwent lung resected pt.2021 ksctva  september, underwent lung resected pt.
2021 ksctva september, underwent lung resected pt.부휘 홍
 
Chronic Obstructive Pulmonary Disease (COPD) by Dr Kemi Dele
Chronic Obstructive Pulmonary Disease (COPD) by Dr Kemi DeleChronic Obstructive Pulmonary Disease (COPD) by Dr Kemi Dele
Chronic Obstructive Pulmonary Disease (COPD) by Dr Kemi DeleKemi Dele-Ijagbulu
 
Pulmonary embolism
Pulmonary embolismPulmonary embolism
Pulmonary embolismMinaBakhtan1
 
Thoracic anesthesia and One Lung ventilation
Thoracic anesthesia and One Lung ventilationThoracic anesthesia and One Lung ventilation
Thoracic anesthesia and One Lung ventilationWasihun Aragie
 
Lung transplantation ppt tanveer bhola bpt 4th year
Lung transplantation ppt tanveer bhola bpt 4th yearLung transplantation ppt tanveer bhola bpt 4th year
Lung transplantation ppt tanveer bhola bpt 4th yearBPT4thyearJamiaMilli
 
Chronic Obstructive Pulmonary Disease (COPD).pptx
Chronic Obstructive Pulmonary Disease (COPD).pptxChronic Obstructive Pulmonary Disease (COPD).pptx
Chronic Obstructive Pulmonary Disease (COPD).pptxIbrahim Ahmed Nur
 
Thoracic anaesthesia
Thoracic anaesthesiaThoracic anaesthesia
Thoracic anaesthesiaAnkit Gajjar
 
thoracicanesthesia-191114091229.pptx
thoracicanesthesia-191114091229.pptxthoracicanesthesia-191114091229.pptx
thoracicanesthesia-191114091229.pptxAkmalFahrezzy1
 
Acute lung injury
Acute lung injury Acute lung injury
Acute lung injury HI HI
 
Acute Respiratory Distress Syndrome
Acute Respiratory Distress SyndromeAcute Respiratory Distress Syndrome
Acute Respiratory Distress SyndromeRikin Hasnani
 
Recent indication for surgery for pulmonary TB
Recent indication for surgery for pulmonary TBRecent indication for surgery for pulmonary TB
Recent indication for surgery for pulmonary TBHussein Elkhayat
 

Semelhante a Lung transplantation.ppt (20)

Lung transplantation
Lung transplantationLung transplantation
Lung transplantation
 
Lung transplantation
Lung transplantationLung transplantation
Lung transplantation
 
Lung-transplant-Part-1_Pawan_Jul-2017_Full.pdf
Lung-transplant-Part-1_Pawan_Jul-2017_Full.pdfLung-transplant-Part-1_Pawan_Jul-2017_Full.pdf
Lung-transplant-Part-1_Pawan_Jul-2017_Full.pdf
 
ICU Care of the Lung Transplant Recipient
ICU Care of the Lung Transplant RecipientICU Care of the Lung Transplant Recipient
ICU Care of the Lung Transplant Recipient
 
Coronary artery bypass grafting following COVID-19 infection
Coronary artery bypass grafting following COVID-19 infectionCoronary artery bypass grafting following COVID-19 infection
Coronary artery bypass grafting following COVID-19 infection
 
Preoperative assessment for cardio thoracic surgery
Preoperative assessment for cardio thoracic surgeryPreoperative assessment for cardio thoracic surgery
Preoperative assessment for cardio thoracic surgery
 
Thoracic surgery anesthesia
Thoracic surgery anesthesiaThoracic surgery anesthesia
Thoracic surgery anesthesia
 
2021 ksctva september, underwent lung resected pt.
2021 ksctva  september, underwent lung resected pt.2021 ksctva  september, underwent lung resected pt.
2021 ksctva september, underwent lung resected pt.
 
Chronic Obstructive Pulmonary Disease (COPD) by Dr Kemi Dele
Chronic Obstructive Pulmonary Disease (COPD) by Dr Kemi DeleChronic Obstructive Pulmonary Disease (COPD) by Dr Kemi Dele
Chronic Obstructive Pulmonary Disease (COPD) by Dr Kemi Dele
 
Pulmonary embolism
Pulmonary embolismPulmonary embolism
Pulmonary embolism
 
Respiration drugs
Respiration drugsRespiration drugs
Respiration drugs
 
Thoracic anesthesia and One Lung ventilation
Thoracic anesthesia and One Lung ventilationThoracic anesthesia and One Lung ventilation
Thoracic anesthesia and One Lung ventilation
 
Ecmo
EcmoEcmo
Ecmo
 
Lung transplantation ppt tanveer bhola bpt 4th year
Lung transplantation ppt tanveer bhola bpt 4th yearLung transplantation ppt tanveer bhola bpt 4th year
Lung transplantation ppt tanveer bhola bpt 4th year
 
Chronic Obstructive Pulmonary Disease (COPD).pptx
Chronic Obstructive Pulmonary Disease (COPD).pptxChronic Obstructive Pulmonary Disease (COPD).pptx
Chronic Obstructive Pulmonary Disease (COPD).pptx
 
Thoracic anaesthesia
Thoracic anaesthesiaThoracic anaesthesia
Thoracic anaesthesia
 
thoracicanesthesia-191114091229.pptx
thoracicanesthesia-191114091229.pptxthoracicanesthesia-191114091229.pptx
thoracicanesthesia-191114091229.pptx
 
Acute lung injury
Acute lung injury Acute lung injury
Acute lung injury
 
Acute Respiratory Distress Syndrome
Acute Respiratory Distress SyndromeAcute Respiratory Distress Syndrome
Acute Respiratory Distress Syndrome
 
Recent indication for surgery for pulmonary TB
Recent indication for surgery for pulmonary TBRecent indication for surgery for pulmonary TB
Recent indication for surgery for pulmonary TB
 

Último

CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentsaileshpanda05
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfDolisha Warbi
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptxNIKITA BHUTE
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfHongBiThi1
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationMedicoseAcademics
 
Employability skills, work experience presentation
Employability skills, work experience presentationEmployability skills, work experience presentation
Employability skills, work experience presentationmarwaahmad357
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfHongBiThi1
 
A presentation on Thermal gravimetry analysis (TGA)
A presentation on Thermal gravimetry analysis (TGA)A presentation on Thermal gravimetry analysis (TGA)
A presentation on Thermal gravimetry analysis (TGA)1922Jaygohel
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaSujoy Dasgupta
 
Forensic Nursing powerpoint presentation
Forensic Nursing powerpoint presentationForensic Nursing powerpoint presentation
Forensic Nursing powerpoint presentationKavitha Krishnan
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communicationskatiequigley33
 
Cure of patients which terminally ill.pdf
Cure of patients which terminally ill.pdfCure of patients which terminally ill.pdf
Cure of patients which terminally ill.pdfrg0000009
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.kishan singh tomar
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...Sujoy Dasgupta
 
Understanding AIDS:a roadmap to well ess
Understanding AIDS:a roadmap to well essUnderstanding AIDS:a roadmap to well ess
Understanding AIDS:a roadmap to well essAbhishekKumar524514
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxkomalt2001
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxNaveenkumar267201
 

Último (20)

CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing student
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
 
Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...
 
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
 
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
 
Employability skills, work experience presentation
Employability skills, work experience presentationEmployability skills, work experience presentation
Employability skills, work experience presentation
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
 
A presentation on Thermal gravimetry analysis (TGA)
A presentation on Thermal gravimetry analysis (TGA)A presentation on Thermal gravimetry analysis (TGA)
A presentation on Thermal gravimetry analysis (TGA)
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
 
Forensic Nursing powerpoint presentation
Forensic Nursing powerpoint presentationForensic Nursing powerpoint presentation
Forensic Nursing powerpoint presentation
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communications
 
Cure of patients which terminally ill.pdf
Cure of patients which terminally ill.pdfCure of patients which terminally ill.pdf
Cure of patients which terminally ill.pdf
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
 
Understanding AIDS:a roadmap to well ess
Understanding AIDS:a roadmap to well essUnderstanding AIDS:a roadmap to well ess
Understanding AIDS:a roadmap to well ess
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptx
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
 

Lung transplantation.ppt

  • 2. Overview : • Introduction • Purpose of lung transplantation • History • Indications • Disease specific selection criteria • Contraindications 2
  • 3. Overview : • Description • Laboratory studies • Donor-related issues • Preoperative care • Post operative care • Complications • Normal results 3
  • 4. Introduction : • Lung transplantation involves removal of one or both diseased lungs from a patient and the replacement of the lungs with healthy organs from a donor • Lung transplantation may refer to single, double, or even heart-lung transplantation . • Lung transplantation is an accepted modality of treatment for end stage lung disease that is unresponsive to medical therapy 4
  • 5. Purpose : • To replace a lung that no longer functions with a healthy lung. • To perform a lung transplantation, there should be potential for rehabilitated breathing function. • Other medical treatments should be attempted before transplantation. • Many candidates for this procedure are dependent on oxygen therapy 5
  • 6. History of procedure : • Animal experimentation by various pioneers, including Demikhov and Metras, in 1940s and 1950s demonstrated that the procedure is feasible technically. • First human lung transplantation was done in 1963. The donation was essentially after cardiac death, and the recipient of the left lung transplant survived only 18 days. 6
  • 7. Cont……….d: • From 1963-1978, multiple attempts at lung transplantation failed because of rejection and problems with anastomotic bronchial and tracheal healing. • The first successful single lung transplant was reported by Dr. Joel Cooper at the University of Toronto in 1986 . 7
  • 8. Cont……….d: • In 1988, Dr. Alexander Patterson described the technique of double-lung transplantation. • Dr. Denton Cooley and associates were the first to attempt heart-lung transplantation in 1968. • First heart-lung transplant in India- 3 May 1999 at Madras Medical Mission. 8
  • 9. AGE DISTRIBUTION OF LUNG TRANSPLANT RECIPIENTS 0 5 10 15 20 25 18-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-65 66+ Recipient Age %oftransplants J Heart Lung Transplant 2008;27: 937-983 9
  • 10. Indication of lung transplantation : • Obstructive lung disease: A. Chronic obstructive pulmonary disease • Restrictive lung diseases: A. Idiopathic pulmonary fibrosis (IPF) B. Interstitial lung disease 10
  • 11. Indication of lung transplantation : • Septic lung disease: A. Cystic fibrosis (CF) B. Bilateral bronchiectasis • Pulmonary vascular disease: A. Primary pulmonary hypertension (PPH) B. Eisenmenger’s syndrome 11
  • 12. Diagnosis of Lung Transplant Recipients in US (1986-2007) 40% 13%13% 8% 14% 2% 4% 1% 4% 1% COPD Alpha I Anti Def IPF Other Cystic Fibrosis IPAH Talcosis BO Eisenmenger's Bronchiectasis J Heart Lung Transplant 2008;27: 937-983 12
  • 13. Disease specific selection criteria COPD- Pt. with BODE index 7 to 10 of at least 1 of the following: 1. FEV1 < 25% predicted ( without reversibility) 2. PaCO2 >55 mm of Hg 3. Elevated pulmonary artery pressure (PAP) 4. Cor pulmonale 13
  • 14. Cont……….d: Other indices shown to correlate mortality- 1)subjective breathlessness 2)weight loss 3)exercise tolerance 4)hospitalization 5) lung morphology all patients requiring hospitalization for exacerberation should be considered for surgery 1 year mortality after hospitalization -23% 14
  • 15. The BODE Index For COPD Can Fam Physician 2008;54:706-11
  • 16. 16
  • 17. Cont……….d:  IPF- • Highest attrition rate with waiting list mortality 30% • Initially, owing to unpredictable nature of course, view was to refer all patients for transplantation at diagnosis • Patients with exercise induced desaturation are ideal candidates 17
  • 18. Cont……….d:  Current consensus- 1) Symptomatic progressive disease despite 3 months of medical therapy 2) Rest or exercise induced desaturation 3) Symptomatic with- VC< 60-70%predicted DLCO < 50-60% pred. 18
  • 19. Cont……….d:  Cystic fibrosis  Prognostic criteria- 1)age per year 2)sex 3)FEV1 4)weight for age 5)Pancreatic insufficiency 6)D.M. 7)S.aureus 8)B.cepacia 9)No. of acute exacerberations 19
  • 20. Cont……….d: • Patients divided into 5 prognostic groups • Only group 1&2 with 5 year survival rate <30% benefited • Resistant B. cepacia infection is absolute contraindication 20
  • 21. Cont……….d:  PPH • Advancement in medical management- reduced need for transplantation • 1990- 10.5% of all cases • 2001- 3.6% of all cases 21
  • 22. Cont……….d: • Criterias for PPH Symptomatic progressive disease despite optimal medical treatment for 3 months Cardiac index < 2 lit/min/m2 Right atrial pessure>15 mm Hg PAP mean > 55 mm Hg 22
  • 23. Cont……….d:  Eisenmengers syndrome • Better prognosis than patients with PPH with similar PAP levels • Epoprostenol therapy improved survival & reduced need for transplantation • Heart -lung transplantation is preferred 23
  • 24. Cont……….d:  Sarcoidosis • Most patients benign course 10-20% permanent sequel • 2.5% of all transplants • Only stage 4 disease is considered • FVC < 50% & FEV1 < 40% 24
  • 25. Cont……….d:  Lymphangioleiomyomatosis • FEV1/FVC < 45% • Average from diagnosis to transplant - 11yr 25
  • 26. Contra-indication (Absolute ): • Malignancy in the last 2 years • Non-curable chronic extra pulmonary infection including chronic active hepatitis B , C , and HIV • Untreatable advanced dysfunction of another major organ system • Current cigarette smoking 26
  • 27. • Poor nutritional status • Poor rehabilitation potential • Significant psychosocial problems • Substance abuse history of medical noncompliance 27
  • 28. Relative Contraindications : • Age : advanced age is associated with higher mortality rates . • Most centers have an age cut-off 50 years for -Heart-lung transplantation, 60 years for- Bilateral lung transplantation, 65 years for -Single-lung transplantation. 28
  • 29. • Ventilator dependence : patients who are dependent on a ventilator prior to the transplant have higher mortality rates . • A prolonged wait while the patient is on a mechanical ventilator may lead to various complications such as infections, cardiovascular de-conditioning. 29
  • 30. • Psychosocial issues : Individuals who currently smoke, abuse drugs, or drink alcohol heavily are not candidates for transplantation. • Patients with other psychosocial issues, such as poor compliance and psychiatric disorders that may complicate post transplant therapy, are not considered good candidates. 30
  • 31. • Infection : patients who have active tuberculosis infection are not candidates for transplantation. • Body weight : Patients who have poor nutritional status and would have a poor outcome following transplantation. 31
  • 32. • Obesity (BMI >30) : also may be a concern because of postoperative atelectasis and pneumonia • Extra pulmonary organ dysfunction : Patients with a significant heart, liver, or kidney disease are not transplant candidates. 32
  • 33. Description : • Single lung transplantation is performed via a standard thoracotomy (incision in the chest wall) with the patient under general anesthesia. • Cardiopulmonary bypass (diversion of blood flow from the heart) is not always necessary for a single lung transplant. 33
  • 34. Cont………..d: • If bypass is necessary, it involves re-routing of the blood through tubes to a heart-lung bypass machine. Double lung transplantation involves implanting the lungs as two separate lungs, and cardiopulmonary bypass is usually required • The patient's lung or lungs are removed and the donor lungs are stitched into place. Drainage tubes are inserted into the chest area to help drain fluid, blood, and air out of the chest. 34
  • 35. Figure Patient positioned for bilateral lung transplant, through a clamshell incision with the arms abducted. The skin incision is depicted in the mammary fold heading laterally toward the mid-axillary line. The dotted line shows the level of the 4th intercostal space. The position of the femoral artery, on both sides, is also marked. The groin is prepped and draped, since during the transplant procedure, an arterial femoral line may become necessary for monitoring or even for cannulation for cardiopulmonary bypass. 35
  • 36. ADULT LUNG TRANSPLANTATION: Indications for Single Lung Transplants (Transplants: January 1995 - June 2007) 50% 28% 2% 1% 2% 7% 10% Alpha-1 COPD CF IPF PPH Re-TX Other* *Other includes: Sarcoidosis: 2.1% Bronchiectasis: 0.4% Congenital Heart Disease: 0.2% LAM: 0.7% OB (non-ReTx): 0.5% Miscellaneous: 5.8% J Heart Lung Transplant 2008;27: 937-983
  • 37. ADULT LUNG TRANSPLANTATION: Indications for Bilateral/Double Lung Transplants (Transplants: January 1995 - June 2007) 24% 14% 18% 8% 28% 6% 2% Alpha-1 COPD CF IPF PPH Re-Tx Other* *Other includes: Sarcoidosis: 3.0% Bronchiectasis: 4.8% Congenital Heart Disease: 1.3% LAM: 1.2% OB (non-ReTx): 1.1% Miscellaneous: 6.6% J Heart Lung Transplant 2008;27: 937-983
  • 38. Laboratory studies : • The following diagnostic tests are usually performed to evaluate a patient for lung transplantation: • Arterial blood gases (ABG ) test: which measures the amount of oxygen that the blood is able to carry to body tissues. 38
  • 39. • Pulmonary function tests (PFTs): which measure lung volume and the rate of air flow through the lungs; the results measure the progress of the lung disease. • Computerized tomography (CT) scan. A chest CT scan is taken of horizontal slices of the chest to provide detailed images of the structure of the chest. 39
  • 40. • Ventilation perfusion scan (lung scan, V/Q scan) is a test that compares right and left lung function • Electrocardiogram (ECG): is performed by placing electrodes on the chest. A recording of the electrical activity of the heart is obtained to provide information about the rate and rhythm of the heartbeat 40
  • 41. • Echocardiogram (ECHO) is performed to evaluate the impact of lung disease on the heart. It examines the chambers, valves, aorta, and the wall motion of the heart. ECHO also provides information concerning the blood pressure in the pulmonary arteries. This information is required to plan the transplantation surgery. 41
  • 42. • Blood test : Complete blood count , Coagulation profile. • HIV, hepatitis B, hepatitis C 42
  • 43. Donor-related issues: • Younger than 65 years for lung transplantation and younger than 45 years for heart-lung transplantation • Absence of severe chest trauma or infection • Absence of prolonged cardiac arrest (heart- lung only) • Minimal pulmonary secretions Negative screens for HIV, hepatitis C, and hepatitis B 43
  • 44. • Blood type (ABO) compatibility • Close match of lung size between donor and recipient • PaO2 > 300 mm Hg on 100% fraction of inspired oxygen • Clear chest radiograph • No history of malignant neoplasms 44
  • 45. Preoperative care: • Preoperative assessment consist of both medical & psychosocial evaluation. • Assessment of patient‘s physical health is assessed to determine candidacy for transplantation. • In preoperative phase the patient is assessed for cardiac output & renal functions . • Psychosocial evaluation focuses on assessing the patient‘s history of compliance with medical therapy & ability to cope with stress. 45
  • 46. Post operative care : • The patient is observed for excessive bleeding. • Monitor vital signs ,ECG ,ABG values ,urine output, O2 level analysis & chest tube drainage. • The patient may be started on mechanical ventilation for 24 to 48 hours. 46
  • 47. • Serum electrolytes ,complete blood count, chest radiographs are obtained daily. • Fluids are restricted. • Lung sounds are auscultated. • Severity of peripheral edema is monitored. • Pain control is important to allow deep breathing & coughing with chest physiotherapy. 47
  • 48. • The patient with lung transplantation is at high risk to develop infection. • So isolation is used to decrease exposure to pathogens. • Monitor the patient for clinical manifestation of infection such as: Change in vital signs especially fever Local infection at i/v site & incision line Changes in respiratory status like excessive secretions, tachypnea,dyspnea 48
  • 49. Immunosuppression • Induction phase- A) ATG B) Selective IL2 receptor antagonists • Maintenance phase- A) Steroid + calceneurin inhibitor B) Steroids ( low dose ) life long C) Tacrolimus for 1-5 years 49
  • 50. Newer drugs 1) Sirolimus (Rapamycine)- An analog of Tacrolimus 2) Everolimus- used in combination with cyclosporin & prednisolone shown to have freedom from biopsy proven acute rejection in 88% cases 50
  • 51. Complications • Causes of respiratory failure after LTx Early • ischemia reperfusion injury • infection • technical problems • acute rejection >3months • Infections • BOS Curr.opin.Crit.care 2006 Feb;12, 19-24 51
  • 52. Ischemia reperfusion injury Most frequent cause of early mortality presents as ALI / ARDS Reduced incidence since 1990- 1) low K- dextran solution 2) nitric oxide added to flush solution 3) prevention of hyperinflation during harvesting 4)controlled reperfusion with leucocyte depletion 52
  • 53. Ischaemia reperfusion injury contd. • Treatment- A) diuretics B) maximal ventilatory support • Newer modalities A) inhaled nitric oxide B) inhaled prostacyclin • Course- resolves in 48-72 hrs 53
  • 54. Infections • Bacterial- A) psuedomonas predominate in early post op(75%) B) nocardia-2.1% C) legionella , mycobacteria rare • routine antibiotic prophylaxis reduced the incidence • sputum cultures & antibiotic sensitivity done every 3 months 54
  • 55. Viral infections CMV predominates • within 30-100 days after transplant • occurs as reactivation or prim. infection (donor) • incidence varies between 13-75% in various studies • routine prophylaxis replaced by close monitoring • Treatment-gancyclovir 5mg/kg for 2-3 weeks55
  • 56. • HSV&VZV can cause pnuemonia • Acyclovir prophylaxis effective in patients not on gancyclovir • EBV related post-transplant lymphoproliferative disease • 4-10% cases • usually fatal outcome • recently Rituximab ( anti CD20 Ab) found effective 56
  • 57. Fungal infections • Aspergillus most common 1) ulcerative trachitis 2) bronchitis 3) pnuemonitis 4) disseminated diesase 5) ABPA- reported • I.V. or aerolised ampho-B used for prophylaxis 57
  • 58. Other rarer organisms • Histoplasma • Sedosporium • Pnuemocystis jirovecii 58
  • 59. Rejection • Acute rejection- • < 7 days onset • low grade fever, dyspnoea • CXR- 1) Clear 2) illdefined infiltrates 3) pleural effusion • reduced FEV1 59
  • 60. Acute rejection • TBLB - gold standard in diagnosis • Noninvasive means-area of active research 1) Cytokine milieu in BAL fluid 2) gene upregulation as a biomarker • Treatment- bolus I.V. steroids + increase in maintenance immunosuppression • role of surveillance bronchoscopy to detect rejection early is controversial 60
  • 61. Chronic rejection  Bronchiolitis Oblitrance Symdrome (BOA) : • Predominantly a small airway disease • occurs in 50% patients surviving for 5 years • onset > 6months • major cause of mortality • CXR- can be normal late cases- bronchiectesis • HRCT- mottled appearance with peripheral lucency 61
  • 62. TBLB- gold standard • Role of induced sputum & BAL- 1) Induced sputum – RANTES levels and eosinophils correlate with BOS development 2) BAL- IL8 & neutrophil levels have negative correlation 62
  • 63. • Treatment- variable course even without treatment • various immunosuppressive regimens tried • macrolides under evaluation 63
  • 64. • Factors associated- 1) CMV pnuemonitis -no. of episodes 2) HLA mismatch 3) GERD- laproscopic fundoplication reduces incidence 64
  • 65. Self care : • Before discharge the patient should be teach about the medication regimen. • The patient should report for fever, dyspnea, cough ,increased sputum production ,chest pain, excessive weight gain, fatigue to physician. During follow up the client is monitored for manifestation of rejection & progress in functional status. 65
  • 66. • Exercise capacity has been the most interesting functional outcome observes in lung transplant recipient . • Typically transplant recipient can walk 100 to 120m/min within 6 months of transplantation. 66
  • 67. Normal results: • Demonstration of normal results for lung transplantation patients include a) adequate lung function, b) improved quality of life, c) lack of infection and rejection. 67
  • 68. http://articles.timesofindia.indiatimes.com/2012-07-31/mumbai/32960286_1_lung-transplants- transplant-team-surgery Cost of Lung Transplantation in India • Surgery alone cost Rs 10 lakh. • The ICU and medications will work up to an equal amount 68